Cambridge Enterprise has licensed key technology to Qkine, a spinout that is working on proteins to control stem cell growth.

Paul Ashley and Brendan Ludden will be responsible for life sciences and physical sciences, respectively.

Lundbeck has taken part in a $67m series C round for Amplyx Pharmaceuticals, which is developing treatments for life-threatening fungal infections.

UCB Pharma scored an exit after the bone disease therapy developer floated at the top of its range, having secured $92.5m in funding over the past two years.

Cardiovascular therapy developer Milestone Pharmaceuticals will use proceeds from the Novo-led round to advance its lead candidate to a phase 3 clinical trial.

Homology Medicines, a startup developing treatments for rare genetic diseases, has closed $83.5m in series B funding, welcoming Novartis as a new investor.

Genetic disease medicine producer BridgeBio Pharma led the carcinoma therapy developer's latest round, having provided an undisclosed amount in December 2016.

AngelMD has put an undisclosed amount into Otomagnetics, a developer of a magnetic injection delivery system based on research at University of Maryland, College Park.

Dermatology product developer and JLabs graduate Sienna Biopharmaceuticals floated at the middle of its range having raised $86m in venture funding.